

Data supplement to Zhang et al. evidence for complement factor H conferring susceptibility to major depressive disorder in Han Chinese. Br J Psychiatry doi: 10.1192/bjp.bp.115.163790

Table DS1 Demographics of MDD cases and controls for expression analyses

	Cases	Controls	<i>P</i>
Number of subjects (n)	53	55	
Age (years), mean (SD)	29.0 (5.9)	31.0 (6.8)	0.41
Gender, male n (%)	18 (34.0)	22 (40.0)	0.33
Smoking status, n (%)	14 (26.4)	17 (30.9)	0.38
Alcoholic misuse, n (%)	0 (0)	0 (0)	
Duration of illness (month) a, mean (SD)	2.9 (1.0)	N/A	
HRSD-17 b, mean (SD)	25.2 (2.1)	N/A	
Number of episodes, mean (SD)	1.4 (0.3)	N/A	
Family history of mood disorders, n (%)	3 (5.6)	N/A	

Note: ^a Duration of illness prior to admission

^b HRSD-17 on admission

Table DS2 Information of selected SNPs genotyped in this study

#	SNP ID	Allele	MAF ^a	Position (Chr. 1)	Note
1	rs800292	C/T	0.329	194908856	tag, V62I
2	rs10801555	A/G	0.122	194926884	tag
3	rs10922096	C/T	0.232	194929082	tag
4	rs10733086	A/T	0.158	194943558	tag
5	rs10737680	A/C	0.329	194946078	tag
6	rs11582939	C/T	0.500	194976780	tag
7	rs2019727	A/T	0.110	194941337	tag
8	rs1410996	C/T	0.433	194963556	tag
9	rs1061170	C/T	0.067	194925860	Y402H
10	rs460184	A/G	0.000	194982960	V1197L
11	rs426736	C/T	0.467	195027040	tag, located in CFHR3

^a MAF - minor allele frequency, in dbSNP CHB dataset (<http://www.ncbi.nlm.nih.gov/SNP/>).

Table DS3 Primers for genotyping the *CFH* SNPs

SNP ID	Primer	Primer sequences (5'>3')
rs800292	PCRU	TTAATGGATTAAGAGCAACCCA
	PCRL	AGGCTATCTATAAATGCCGCC
	SNP	TCTCCCTTCCTGCATACCATTATTA
rs10801555	PCRU	TTAAAAGGAAAAACCTTATCAAGGA
	PCRL	TCAAATGATTGATTCCAATGTACA
	SNP	gactCTGTACCCTCATTATCTGCCTAAAC
rs10922096	PCRU	GCTGTAGTTTCCTTTAAAATAGTCATT
	PCRL	AATCATTCAGATGGCACTAGTAATT
	SNP	t(gact) ₂ CCAGATAAATCACAGAATATCAATT
rs10733086	PCRU	GAGGAAAAATATCAGATAAGTAACTTTAATG
	PCRL	TATAATAACAAACATTCTGTATGCTC
	SNP	ct(gact) ₃ TAGACAAAACATATGTCTTCTTGAC
rs10737680	PCRU	CCTTGTGTTGATTAAAGCCT
	PCRL	TTATAAGACTATCAGGTTACATGC
	SNP	act(gact) ₄ TCTTTGCTGCAAACCCTACTGTCTC
rs11582939	PCRU	AAATTAGTTTCAATTTACATCATCTTG
	PCRL	ATGAGTAGAGGCAGCTGTGC
	SNP	(gact) ₆ TTAAGCATCCTCTGATGTATATTCT
rs2019727	PCRU	CTCATGATATTCCTCAAGTCTT
	PCRL	TAAGTAAAAATTACTAATGGATCTGGC
	SNP	(gact) ₇ TAAACCCATCCCTTCTCTCATGT
rs1410996	PCRU	ATGAGATTTACAGTGTGAAGTCCG
	PCRL	AGGGTTGGTGGGCCACAG
	SNP	(gact) ₈ TGACTCAGTCCCTGACTACCTCATG
rs1061170	PCRU	TTATGGTCCTTAGGAAAATGTTATTT
	PCRL	ATGGCAGGCAACGTCTATAG
	SNP	(gact) ₉ TTTGAAAATGGATATAATCAAAAT
rs460184	PCRU	AATGTGTGAGAACGTGATGAAA
	PCRL	TTTTTTATTTTCAGATCCGTGTG
	SNP	(gact) ₁₀ ATATCCCCGTTTACACACAAATTCA
rs426736	PCRU	CCATAATCATTGTGGCTTATATTTT
	PCRL	AAGCCAGTAATATAGGTATACTTCCAGA
	SNP	t(gact) ₁₁ GAGTTGTGTTGCTTCAAGTTCATAG

Note: PCR amplification primers were marked by “PCRU” and “PCRL”, whereas SNP-specific oligonucleotide primer was marked by “SNP”. In the “(gact)_n”, n means the number of “gact” repeats.

Table DS4 Plasma C3, C4 and AP activity in MDD cases and healthy controls

	Cases	Controls	<i>P</i> ^a	<i>P</i> ^b	Power ^c (%)
C3 (pg/ml)	2735.3 (964.8)	2225.1 (726.3)	0.002	0.004	82.4
C4 (pg/ml)	1619.3 (754.3)	1352.5 (503.4)	0.032	0.016	77.3
AP activity (%)	82.1 (20.3)	73.9 (21.8)	0.046	0.078	23.5

^a Raw *P* values

^b The *P* values were adjusted for age, sex and smoking status

^c Observed power

Table DS5 Distributions of genotypes and alleles of *CFH* variants in stage 1 study (sample set 1: 1012 MDD cases and 1196 controls)

#	SNP	Sample	Genotype, n (%)			<i>P</i>	Allele, n (%)		<i>P</i>	Odds ratio (95%CI)
1	rs800292		T/T	T/C	C/C	0.60	T	C	0.39	1.04 (0.92-1.17)
		Cases	156 (15.4)	520 (51.4)	336 (33.2)		832 (41.1)	1192 (58.9)		
2	rs1061170		C/C	C/T	T/T	0.004^a	C	T	0.001^a	1.50 (1.17-1.92)
		Cases	6 (0.6)	139 (13.7)	867 (85.7)		151 (7.5)	1873 (92.5)		
3	rs10801555		A/A	A/G	G/G	0.03	A	G	0.009	1.38 (1.08-1.76)
		Cases	7 (0.7)	135 (13.3)	870 (86.0)		149 (7.4)	1875 (92.6)		
4	rs10922096		T/T	T/C	C/C	0.04	T	C	0.03	1.20 (1.02-1.42)
		Cases	36 (3.6)	255 (25.2)	721 (71.2)		327 (16.2)	1697 (83.8)		
5	rs2019727		T/T	T/A	A/A	0.94	T	A	0.07	1.03 (0.83-1.26)
		Cases	8 (0.8)	167 (16.5)	837 (82.7)		183 (9.0)	1841 (91.0)		
6	rs10733086		A/A	A/T	T/T	0.03	A	T	0.008	1.34 (1.08-1.66)
		Cases	15 (1.5)	161 (15.9)	836 (82.6)		191 (9.4)	1833 (90.6)		
7	rs10737680		C/C	C/A	A/A	0.96	C	A	0.87	1.00 (0.90-1.14)
		Cases	172 (17.0)	512 (50.6)	328 (32.4)		856 (42.3)	1168 (57.7)		
8	rs1410996		T/T	T/C	C/C	0.68	T	C	0.48	1.04 (0.93-1.18)
		Cases	167 (16.5)	515 (50.9)	330 (32.6)		849 (41.9)	1175 (58.1)		
9	rs11582939		T/T	T/C	C/C	0.09	T	C	0.05	0.89 (0.79-1.00)
		Cases	228 (22.5)	513 (50.7)	271 (26.8)		969 (47.9)	1055 (52.1)		
11	rs426736		C/C	C/T	T/T	0.04	C	T	0.03	0.88 (0.78-0.99)
		Cases	218 (21.5)	521 (51.5)	273 (27.0)		957 (47.3)	1067 (52.7)		
		Controls	313 (26.2)	581 (48.6)	302 (25.3)		1207 (50.5)	1185 (49.5)		

Note: ^a *P* values were presented after Bonferroni correction
Significance was presented in bold

Fig. DS1 Ct values of *GAPDH* between MDD patients and controls. Ct values representing the expression levels of the *GAPDH* gene in human whole blood samples. MDD, major depressive disorder; CTL, controls; ns, no significance




Fig. DS2 Linkage disequilibrium plot consisting of 10 SNPs at the *CFH* gene and its region plot. Pairwise linkage disequilibrium (LD) was computed for all possible combinations of the 10 SNPs using the values of D' and r^2 . The individual square showed the $100 \times D'$ (or r^2) value for each SNP pair. Rs460184 was not included due to the deviation from HWE.

